CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025)
CapsoVision recorded quarterly Preferred Stock Liabilities of $143.6 million in Q2 2025, little changed quarter-over-quarter from $143.6 million in Q4 2024, and up 11.66% year-over-year from $128.6 million in Q2 2024.
CapsoVision's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $143.6 million for Q2 2025.
- In Q2 2025, Preferred Stock Liabilities rose 11.66% year-over-year to $143.6 million; the TTM figure through Jun 2025 stood at $143.6 million (up 11.66% YoY), while the FY2024 annual figure was $143.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $143.6 million for Q2 2025 at CapsoVision, roughly flat from $143.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $143.6 million in Q4 2024 to a low of $128.6 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | CapsoVision | 167.59 Mn | 157.48 Mn | 1.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 143.63 Mn |
| Dec 31, 2024 | 143.63 Mn |
| Sep 30, 2024 | 138.63 Mn |
| Jun 30, 2024 | 128.63 Mn |